key: cord-0326297-etqau0sf authors: Cai, Ling; Liu, Hongyu; Huang, Fang; Fujimoto, Junya; Girard, Luc; Chen, Jun; Li, Yongwen; Zhang, Yuan; Deb, Dhruba; Stastny, Victor; Kuo, Christin S.; Jia, Gaoxiang; Yang, Chendong; Zou, Wei; Alomar, Adeeb; Huffman, Kenneth; Papari-Zareei, Mahboubeh; Yang, Lin; Drapkin, Benjamin; Akbay, Esra; Shames, David S.; Wistuba, Ignacio I.; Wang, Tao; Xiao, Guanghua; DeBerardinis, Ralph J.; Minna, John D.; Xie, Yang; Gazdar, Adi F. title: Relationship Between Neuroendocrine and Immune Gene Expression in Small Cell Lung Cancer date: 2020-07-29 journal: bioRxiv DOI: 10.1101/2020.07.28.225763 sha: 30f7f655df7846b6bd07ef70345208a278c83d4c doc_id: 326297 cord_uid: etqau0sf Small cell lung cancer (SCLC) is classified as a high-grade neuroendocrine (NE) tumor, but a subset of SCLC has been termed “variant” due to the loss of NE characteristics. In this study, we computed NE scores for patient-derived SCLC cell lines and xenografts, as well as human tumors. We aligned NE properties with transcription factor-defined molecular subtypes. Then we investigated the different immune phenotypes associated with high and low NE scores. We found repression of immune response genes as a shared feature between classic SCLC and pulmonary neuroendocrine cells of the healthy lung. With loss of NE fate, variant SCLC tumors regain cell-autonomous immune gene expression and exhibit higher tumor-immune interactions. Pan-cancer analysis revealed this NE lineage-specific immune phenotype in other cancers. Additionally, we observed MHC I re-expression in SCLC upon development of chemoresistance. These findings provide a new framework to guide design of treatment regimens in SCLC. line encyclopedia (CCLE) (25) and found higher levels of activating serine 536 phosphorylation on p65 (26) 137 in low NE-score SCLC lines (Figure 2c ). Our 50-gene signature derived from lung cancer cell line mRNA data (Table S1) contains several genes 140 with immune related functions that were found to highly express in variant SCLC. Some are involved in 141 cytokine signaling; for example, IL18 encodes for a proinflammatory cytokine (27), and OSMR encodes for 142 a receptor for oncostatin M and . Furthermore, many of these genes are involved with 143 immunosuppressive processes, including NT5E (29), TGFBR2 (30), ANXA1 (31), EPHA2 (32) , HFE (33) 144 and LGALS3 (34). Our pathway analyses indicates that beyond these genes included in the NE expression 145 signature, there is a broad immune program concertedly upregulated in low NE-score SCLC samples. We 146 extended our analysis to a few immune gene sets that were previously identified to express cell 147 autonomously in cancer. These gene sets include the following: SPARCS genes (stimulated 3 prime 148 antisense retroviral coding sequences) reported to express in mesenchymal tumors and mediate interferon-149 gamma signal amplification (35); "parainflammation" (PI) genes in epithelial tumor cells (36); and 150 senescence-associated secretory phenotype (SASP) genes (37) that reinforce the senescence arrest, alter 151 the microenvironment, and trigger immune surveillance of the senescent cells (38) . We observed that the 152 expression these genes also negatively correlate with NE scores in SCLC despite little overlap among 153 genes in these various sets ( Figure S2 ). While the expression of neuronal program genes in in high NE-score SCLCs can be attributed to the NE 156 lineage, we examined single-cell RNA-seq (scRNA-seq) data from the healthy human lung epithelial cells the presence of interferon stimulation, PNECs would also be less primed for further activation of ISGs. It 165 has been estimated that 10% of the genes in the human genome have the potential to be regulated by IFN, 166 many ISGs work in immune defense against viral infection, but some could be hijacked by viruses (41). As 167 some PNECs are rare stem cells, we reason that ISG repression could lower their risk from viral infection. In 168 the context of the current COVID-19 pandemic, we examined scRNA-seq data from Ouadah et al., who We saw higher expression of PD-L1 (CD274) in low NE-score SCLCs ( Figure S5a) . Furthermore, genes 189 from an IFN-gamma related signature that has been shown to predict PD-1 blockade response in multiple 190 cancer types (46) are highly expressed in low NE-score SCLC tumors across multiple datasets (Figure 3c ). We also examined a list of 21 immune checkpoint genes (47), immune suppressive cytokines (IL-10 and 192 TGF-beta), and their receptors (48), for their association with NE scores. We found that these genes also 193 have higher expression in low NE-score SCLC tumors (Figure 3c) . Finally, the expression of 995 194 immunosuppressive genes from the Human Immunosuppression Gene Atlas (47) were assessed and again, 195 the majority of these genes exhibit negative correlation between mRNA expression and NE scores across 196 different SCLC tumor datasets ( Figure S5b and Table S3 ). Besides gene expression-based analyses, we also performed immunohistochemistry (IHC) with our 9 SCLC 199 tumor samples to quantify tumor infiltrating CD8+ and CD4+ T cells (Table S2) Pan-cancer analyses for NE score expression and immune response genes. These findings had prompted us to examine other cancer types to see whether immune gene repression is 209 seen in other NE tumors and whether "variant" subtype from NE lineage loss could also be observed 210 (Figure 4c) . A recent study identified "SCLC-like" epithelial tumors in pan-cancer samples using a principal 211 component analysis-based approach. They found that tumors across many lineages with a higher "SCLC-212 like" score had lower immune gene expression (49). We applied our NE scoring method across all cancer 213 lineages ("pan-cancer" analysis) to compute NE scores and assess their relationship with immune 214 phenotypes. In pediatric (Therapeutically Applicable Research to Generate Effective Treatments -TARGET) 215 and adult (The Cancer Genome Atlas -TCGA) pan-cancer studies (50), neuroendocrine tumor 216 neuroblastoma (NBL), as well as pheochromocytoma & paraganglioma (PCPG) were identified as 217 containing the highest NE scores (Figures 5a-b) . Tumors of glial origin, including Low Grade Glioma (LGG) 218 and Glioblastoma Multiforme (GBM) also have high NE scores. Besides these NE/glial tumors, a small 219 number of high NE-score samples were observed for bladder urothelial carcinoma (BLCA), breast invasive 220 carcinoma (BRCA), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic 221 adenocarcinoma (PDAC) and stomach adenocarcinoma (STAD), for which it is also known that 222 neuroendocrine tumors, while uncommon, still comprise a small proportion of the cases (Figures 5a-b) . Previous immunogenomic analysis had classified pan-cancer TCGA samples into six immune subtypes (51). We found samples from the "immunologically quiet" subclass have the highest NE score, followed by the 225 "lymphocyte depleted" subclass (Figure 5c) . We further assessed the relationship between NE scores and 226 the tumor-infiltrating lymphocytes and leukocyte regional fractions previously reported for the pan-cancer 227 samples (51), these immune metrics negatively correlate with NE scores across all samples (Figure 5d) 228 and also within specific tumor types ( Figure S6 ). We took a close examination of NBL using cell line expression data from CCLE (25) MHC I re-expression in chemoresistant SCLC As it was previously observed that variant SCLC cell lines were frequently derived from patients whose 241 tumors had relapsed on chemotherapy (17), we wondered if the development of chemo-resistance in 242 tumors was associated with the altered expression of immune genes, especially MHC I. Five sets of data 243 with origin-matched chemosensitive and chemoresistant samples were examined to address this question. In 2017, using a genetically engineered mouse model (GEMM), Lim et al showed that Notch-active SCLC 245 cells were more chemoresistant (18). Using their data we found the Notch active SCLC cells had switched 246 from ASCL1+ to YAP1+, have reduced NE scores and increased expression of ISGs and MHC I genes 247 (Figure 6a) . We next examined a series of preclinical models we and others have developed for human 248 SCLC. Classic, high NE-score SCLC cell lines predominantly grow as floating aggregates in culture, but 249 contain a small proportion of cells growing adherently in a monolayer. By selecting for adherent growth, we 250 generated an adherent subline H69-AD(/NCI-H69-AD) from parental, chemosensitive H69(/NCI-H69) cells 251 (Figure 6b) . Increased resistance to Cisplatin (~10 fold) and Etoposide (~6 fold) was observed in H69-AD 252 compared to the parental H69 cells (Figure 6c) . We found H69-AD had transitioned to become a low NE-253 score (-0.02) YAP1+ variant line compared to the parental high NE-score (0.91) classic ASCL1+ line. Both ISGs and MHC I genes were found to have increased expression in H69-AD (Figure 6d) . In a previous 255 study, Cañadas et al. also derived sublines from H69. Hepatocyte growth factor treatment was used to 256 induce mesenchymal transition of H69 cells, resulting in H69-M lines that were found to be chemoresistant 257 both in vitro and in vivo (53). From their dataset, we also found MHC I expression increased in H69-M 258 compared to parental H69 cells. There was some increase in ISGs too, but less prominent compared to 259 H69-AD from us. Notably, although YAP1 expression increased in H69-M, ASCL1 levels did not change 260 ( Figure 6d) . As the fourth set of data, PDX models established sequentially from SCLC tumors 261 ("Drapkin_2018") collected before and after chemotherapy from the same patient (54) were examined. In PDXs from patient MGH1518 for which chemoresistance had developed in the relapsed sample, we found 263 upregulation of MHC I, but not ISGs (Figure 6d ). Of note, this relapsed sample maintained a high NE score, 264 but expressed higher levels of MYC, consistent with previous findings that MYC mediates chemoresistance 265 (54). Lastly, we generated a set of subcutaneous xenograft models from a high NE-score human SCLC cell 266 line NCI-H1436 with or without selection for resistance to Cisplatin and Etoposide in the mice (Figure 6e ). Compared to the parental xenograft, the drug resistant xenografts maintained ASCL1 expression but In this study, we examined NE properties of patient-derived SCLC cell lines, PDXs and human tumors 282 based on NE scores estimated from a gene expression signature. Currently, it is believed that Notch 283 activation drives the lineage transition from ASCL1+ to NEUROD1+ to YAP1+ subtype (55) whereas 284 POU2F3+ SCLC is a standalone subtype originated from tuft cells (56). While we observed mutually 285 exclusive patterns of ASCL1 and NEUROD1 expression in cell lines, their co-expression was identified in 286 many patient tumors. Our IHC results further revealed intratumoral heterogeneity in such tumors, 287 suggesting ongoing lineage transition in primary treatment naïve tumors. From alignment of NE scores and 288 molecular subtype-specific TF expression, we observed rare high NE-score POU2F3+ tumors in three 289 independent datasets, raising the possibility that POU2F3+ tumors could also arise from NE lineage. PNECs can function as "cells of origin" for SCLC (57-60), the gene expression similarities between PNECs 294 and SCLC suggests many of the SCLC properties could be tied to PNEC characteristics. We confirmed ISG 295 repression in PNECs relative to other lung epithelial cells through examination of scRNA-seq data from 296 healthy human lung. ISGs provide viral defense for cells but some can be hijacked by viruses (41). Since PNECs assume stem cell roles for tissue regeneration after injury (7), lowering expression of ISGs and 298 other genes involved in viral entry presumably play some role in self-protection. Like SCLC, PNECs can 299 switch from ASCL1+ to YAP1+ through Notch activation, but in the context of tissue repair (7). Our findings 300 suggest that the increase of cell autonomous immune gene expression as high NE-score SCLCs transition 301 to low NE-score SCLCs is mirroring the changes that normally take place during the transdifferentiation of 302 PNECs to other lung epithelial cell types, and in SCLC, this had in turn led to an increased tumor-immune 303 interaction. Interestingly, our pan-cancer analysis had extended this finding of reciprocal relationship between neuroendocrine and immune gene expression to other cancer types. For NBL, a cancer that had 305 not previously been classified based on NE properties, we were able to identify more inflammatory variant 306 tumors with loss of NE lineage gene expression. It would be interesting to explore more of such molecular 307 similarities between SCLC and other tumors with NE/neuronal lineage. The full repertoire of immune evasion strategies employed by SCLC remains to be elucidated. However, our 310 results tying together with current clinical treatment findings raise several important questions and 311 paradoxes. The first paradox is that we found a depletion of immune infiltrates in high NE-score SCLC 312 tumors and other neuroendocrine tumors (NETs), associated with down regulation of MHC I expression. While this MHC I expression explains the presence of very few T cells, it raises the question of how high 314 NE-score NETs evade natural killer cells that normally would recognize the "missing self" that such MHC I 315 expression loss conveys (61). Thus, we feel the high NE-score low-MHC I expression pairing indicates we 316 need to understand how natural killer cell mechanisms are avoided in NET pathogenesis. The second 317 paradox is that low NE-score "variant" SCLCs appear to be associated with expression of MHC I and a 318 more immune infiltrated tumor microenvironment, yet clinical trials of immune checkpoint blockade do not 319 clearly show these are the tumors responding to such therapy. Since we found these tumors also express 320 many immunosuppressive genes it will be important to know which of these immunosuppressive gene 321 functions need to be targeted to achieve anti-tumor immune responses. Finally, we observed expression of 322 MHC I in selected SCLC samples with chemoresistance and increased MYC expression even without 323 changes in ASCL1 expression. We need to know if immunosuppressive mechanisms are the same or 324 different in the high vs. low NE-score SCLC resistant to chemotherapy. We conclude, that some 30 years 325 after the first description of "classic" (high NE-score) and "variant" (low NE-score) SCLCs there are 326 important links between these NE phenotypes and the expression of immune phenotypes, and between 327 similar gene expression profiles of SCLC and pulmonary neuroendocrine cells. Importantly, these 328 correlations identify important problems to be solved of clinical therapeutic translational relevance. 332 Table 1 . Datasets used for analyses PDX, Patient-deived Xenografts; FACS, Fluorescence-activated cell sorting; scRNA-seq, Single-cell RNA sequencing; * cells; -Note that CCLE datasets were used in multiple analyses with different numbers of cell lines; ^ In Lim_2017, Rb1 flox/flox ;p53 flox/flox ;p130 flox/flox ;R26 mTmG ; Hes1 GFP/+ GEMM SCLC tumors were initiated by Ad-CMV-Cre, sorted by Tomato and GFP to obtain relatively pure tumor cells. Cancer type-specific scatter plots of NE scores with tumor-infiltrating lymphocytes regional fraction (a) or 451 leukocyte fraction (b) estimated by Thorsson, Gibbs, et al. (51) in TCGA samples. Computation of NE score The construction of the original NE signature has been described by Zhang, Girard et al.(22) . In this study 469 this signature has been updated with expression data from RNA-seq experiments. A quantitative NE score 470 can be generated from this signature using the formula: NE score = (correl NE -correl non-NE)/2 where 471 correl NE (or non-NE) is the Pearson correlation between expression of the 50 genes in the test sample and expression of these genes in the NE (or non-NE) cell line group. This score has a range of −1 to +1, where 473 a positive score predicts for NE while a negative score predicts for non-NE cell types. The higher the score 474 in absolute value, the better the prediction. All heatmaps were generated by R package "ComplexHeatmap"(71). Other R packages used for 494 visualization include "ggplot2" (72), "ggridges" (73), "ggrepel" (74), "ggpubr" (75), "treemap" (76), "RColorBrewer" (77), "jcolors" (78) and "patchwork" (79). Expression data 498 . Drapkin_2018 (54) was downloaded from GEO with accession id GSE110853; Rudin_2012 (9) was 499 obtained from the authors; George_2015 (10) was obtained from a supplementary table of the original 500 publication; Jiang_2016 (62) was downloaded from GEO with accession id GSE60052; IGC's Expression 501 Project for Oncology -expO (GSE2109) and Rousseaux_2013 (GSE30219) (64) was processed 502 previously for the lung cancer explorer (LCE) (63). Pan-cancer data from TCGA and TARGET was 503 downloaded from Toil xena hub (50). For data from GEO, R package GEOquery (80) was used for 504 extracting the expression and phenotype data. Quantile normalization was performed for bulk expression 505 data by running the "normalize.quantiles" function from R package "preprocessCore" (81). Library size 506 normalization was performed for author-processed scRNA-seq data by running the "library.size.normalize" 507 function from R package "phateR" (82). Travaglini_2020 (39) was downloaded from Synapse with 508 accession id syn21041850. FACS-sorted SmartSeq2 data was used. Cell types with less than 10 cells were 509 removed from analyses. Gene set "REST ENCODE" is from the "ENCODE_and_ChEA_Consensus_TFs_from_ChIP-X" library; and 517 "IFNA-BT2" and "IFNG-BT2" are from the "LINCS_L1000_Ligand_Perturbations_up" library. Both libraries 518 were downloaded from Enrichr (24). Top 25 genes from leading edge and are common to all SCLC datasets 519 were selected for heatmap visualization. For ISGs, the leading edge genes from "IFNA-BT2" and "IFNG-520 BT2" were first combined and then the top 25 genes were selected. Mouse ISGs, from Cilloniz et al. (83) , was identified from interferome (84) by specifying "mouse" as the 523 species of interest and "lung" as the organ of interest. An unfiltered ISG set was used for Figure 6A . Pathologic diagnosis was based on WHO criteria. Lung cancer staging for each patient was performed 545 according to the AJCC Cancer Staging Manual, 8th edition, and was based on findings from physical 546 examination, surgical resection, and computed tomography of the chest, abdomen, pelvis, and brain. The 547 following information was collected from the patients' medical records: age, gender, clinical stage, 548 pathologic diagnosis, differentiation, lymph node status, metastasis, smoking status, and overall survival 549 time. Resected lung and lymph node tissues were immediately immersed in liquid nitrogen until RNA 550 extraction. Immunohistochemistry -histology and immunohistochemistry 553 Tissue blocks, once collected, were reviewed by staff thoracic pathologist to confirm SCLC histology. Consecutive four-micrometer-thick tissue sections were cut for immunohistochemistry. IHC staining was 555 performed with a Bond Max automated staining system (Leica Microsystems Inc., Vista, CA) using IHC 556 parameters optimized previously. Antibodies used in this study included ASCL1 (dilution 1:25; Clone 557 24B72D11.1, BD Biosciences, Catalog # 556604), NEUROD1 (dilution 1:100; Clone EPR20766, Abcam, The lymphocyte cells expressing CD4+ and CD8+ were counted by a pathologist using Aperio Image Cisplatin (reduced from EC due to toxicity). Specifically, a million H1436 cells were resuspended in 100 µl 636 mixture of serum-free RPMI 1640 and Matrigel (BD Bioscience #356237) at 1:1 ratio and immediately 637 injected in the flank of 6-8-week-old female NSG mouse (Jackson Laboratory #005557). Mice were 638 randomized after tumor cell injection. Treatment starts after a week when the tumor becomes palpable. 5 639 mg/kg/w Cisplatin (Sigma P4394) in saline, 10 mg/kg/w Etoposide (Sigma E1383) in 30% PEG 300 (Sigma 202371) were freshly prepared and administered by intraperitoneal injection, for 4 cycles in total to obtain 641 the first group of chemoresistant tumors. An additional 4 cycles of Cisplatin were administered in a second 642 group of mice to obtain tumors with further potentiated chemoresistance. To harvest the tumor, 10 ml 643 digestion media was used per mouse. This was prepared freshly by supplementing 9 ml HBSS with 1 ml 644 type IV collagenase, 50 µl DNase II and 50 µl 1 M CaCl 2 . Tumors were collected and placed in HBSS 645 immediately following dissection. A fraction of the tumor was cut into a few pieces and flash-frozen in liquid 646 nitrogen to be saved in aliquots for molecular assays. The remaining chunk was finely minced with a sterile 647 scalpel blade. For re-implantation, the minced tissue was resuspended in digestion media, rotated at 37 °C 648 for 20 min, filtered through a 40 µm filter, centrifuged at 300x g for 5 min. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. LAG3 TAGAP CXCL10 STAT1 GZMB ADORA2A ARHGEF5 BTLA CD160 CD244 CD27 CD274 CD276 CD47 CD80 CEACAM1 CTLA4 GEM HAVCR2 ICOS IDO1 LAG3 PDCD1 TNFSF4 VSIR VTCN1 IL10 IL10RA IL10RB TGFB1 TGFB2 TGFB3 TGFBR1 TARGET_NBL ASCL1 YAP1 SNAP25 SYP RUNDC3A ACTL6B CHGA CELF4 SCAMP5 SYN1 AP3B2 SCG3 BEX1 ELAVL3 SEZ6 SOGA3 STXBP5L MAPK8IP1 PTPRN2 RTN2 GPRIN1 CHGB CELF3 CPLX2 SYT14 CRMP1 GNG4 TRIM22 IFITM1 CASP10 SP100 SP110 IFITM2 HLA−E CTSC IL32 LGALS9 BST2 SPATS2L HLA−DMA LAP3 ICAM1 SAMD9 TNFSF10 C1S TNFAIP3 (this study) TRIM22 IL32 SERPINB9 SPATS2L TRIM38 IFI44L F3 ANTXR1 TNFRSF9 AIG1 BEND6 MSRB2 ADAM19 EPHA3 HERC3 ANXA1 CD44 IFITM3 CCND1 IL1RN ICAM1 BST2 PTGES TLR2 REL BLNK MMP7 OAS2 OAS1 CD14 PLAT ITGA2 TNFRSF12A PPARG PLAUR CXCL10 IFIT3 LGMN HMOX1 MX1 IFIT2 PLA2G2A PLA2G2D IFIT1 MX2 ISG15 IL33 OAS3 CXCL9 AIM2 SCARB1 NOX1 CD276 TIRAP RETNLB IL1R1 NFKB2 SGMS2 ITGA5 BST2 CSF1 XAF1 CX3CL1 PLAU IL15RA IL15 SERPINE1 IFNGR1 FOSL2 NAMPT CD82 CXCL11 CD40 CCL2 CXCL10 IFIT3 GM2A STAT3 MX1 TAPBP IFIT2 NFE2L2 MUC1 CSTB TAP1 STAT1 IGFBP7 IL6 ACVRL1 IRF1 ISG15 KLF6 TNFRSF9 CLU NINJ1 B2M KRT8 RHOB PNRC1 BIRC2 HIF1A PSEN1 ATF3 PVR GAS6 DNAJB4 DDR1 IFNAR1 ATP2C1 KDM6B ATP2A2 GADD45A RCAN1 Goblet (233) Differentiating Basal (43) Ciliated (551) Club (898) Basal (240) Signaling Small-cell lung cancer: what we know, what we need to know 703 and the path forward Recalcitrant Cancer Research Act of Tsao 709 MS, Wistuba I, Panel WHO. The 2015 World Health Organization Classification of Lung Tumors: Impact 710 of Genetic, Clinical and Radiologic Advances Since the 2004 Classification ASCL1 is a 715 lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers An 719 achaete-scute homologue essential for neuroendocrine differentiation in the lung Number and proliferation of 722 neuroendocrine cells in normal human airway epithelium Neuroendocrine Cells Are Stem Cells Regulated by Rb, p53, and Notch A small-cell lung cancer genome with complex signatures of 732 tobacco exposure Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene 739 in small-cell lung cancer Comprehensive genomic profiles of small cell lung cancer Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA 756 in human small-cell lung cancer An Evolutionarily Conserved Function of Polycomb Silences the MHC 762 Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer Tumor Mutational Burden and Response Rate to PD-1 Immunotherapeutic approaches for small-cell lung cancer Epub 2020/02/15 Characterization of variant subclasses of cell lines 771 derived from small cell lung cancer having distinctive biochemical, morphological, and growth 772 properties Establishment and identification of small cell lung cancer cell lines having classic and variant features MYC family 777 DNA amplification in 126 tumor cell lines from patients with small cell lung cancer Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer Small-cell lung cancer: what we know, what we need to know 785 and the path forward 789 suppresses anti-tumor immunity by regulating PTGS2 (COX-2) The hemochromatosis protein HFE 20 years later: 841 An emerging role in antigen presentation and in the immune system Galectin-3 Shapes Antitumor 845 Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid 846 Dendritic Cells 852 Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses Widespread 856 parainflammation in human cancer Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS 860 and the p53 tumor suppressor Control of the senescence-associated secretory phenotype by NF-kappaB 864 promotes senescence and enhances chemosensitivity A molecular 868 cell atlas of the human lung from single cell RNA sequencing. bioRxiv Negative regulation of Yap during 870 neuronal differentiation LY6E 878 impairs coronavirus fusion and confers immune control of viral disease TMPRSS2: A potential target for treatment of 880 influenza virus and coronavirus infections Systematic RNA 886 interference reveals that oncogenic KRAS-driven cancers require TBK1 An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment 892 in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors IFN-gamma-897 related mRNA profile predicts clinical response to PD-1 blockade HisgAtlas 1.0: a human 900 immunosuppression gene database. Database (Oxford) Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares 906 Susceptibilities with Hematological Malignancies Toil 911 enables reproducible, open source, big biomedical data analyses The Immune Landscape of Cancer The genetic landscape of high-risk 929 neuroblastoma Targeting epithelial-to-mesenchymal 933 transition with Met inhibitors reverts chemoresistance in small cell lung cancer Genomic and Functional 940 Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts MYC Drives Temporal Evolution of Small Cell Lung 945 Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell POU2F3 is a master regulator of a tuft cell-like 949 variant of small cell lung cancer Characterization of the cell of origin for small cell lung 953 cancer Origins, genetic landscape, and emerging therapies of small cell 956 lung cancer The comparative pathology of genetically engineered mouse 965 models for neuroendocrine carcinomas of the lung Innate or adaptive immunity? The example of natural killer cells Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung 974 LCE: an open web portal to explore gene 978 expression and clinical associations in lung cancer Ectopic activation of germline and placental genes identifies aggressive metastasis-983 prone lung cancers NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug 988 combination Neural Progenitors in Human Cerebral Organoids through Activation of the Innate Immune Receptor 992 TLR3 GOrilla: a tool for discovery and visualization 995 of enriched GO terms in ranked gene lists The Gene Ontology C. The Gene Ontology Resource: 20 years and still GOing strong REVIGO summarizes and visualizes long lists of gene 1001 ontology terms An algorithm for fast preranked gene set enrichment analysis using cumulative 1004 statistic calculation. bioRxiv Complex heatmaps reveal patterns and correlations in 1006 multidimensional genomic data Wilke CO. ggridges: Ridgeline Plots in 'ggplot2 Automatically Position Non-Overlapping Text Labels with 1011 'ggplot2 ggpubr: 'ggplot2' Based Publication Ready Plots Treemap Visualization. 2017. 1014 77. Neuwirth E. RColorBrewer: ColorBrewer Palettes Colors Palettes for R and 'ggplot2', Additional Themes for 1016 'ggplot2'. 2020. 1017 79. Pedersen TL. patchwork: The Composer of Plots GEOquery: a bridge between the Gene Expression Omnibus (GEO) and 1019 preprocessCore: A collection of pre-processing functions Visualizing structure and transitions in high-1024 dimensional biological data Molecular signatures associated with Mx1-mediated resistance to highly pathogenic influenza virus 1028 infection: mechanisms of survival Interferome v2.0: an updated database of annotated interferon-regulated genes The Molecular 1035 Signatures Database (MSigDB) hallmark gene set collection Knowledgebase for the Laboratory Mouse GSVA: gene set variation analysis for microarray and RNA-1041 seq data Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports 1046 Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients G-protein coupled receptor family C, group 5, 1051 member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of 1052 patients with chronic obstructive pulmonary disease and non-small-cell lung cancer Development of an Immune-Pathology 1057 affy--analysis of Affymetrix GeneChip data at the 1060 probe level Evolving gene/transcript definitions significantly alter the interpretation of 1064 GeneChip data 1067 STAR: ultrafast universal RNA-seq aligner Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and 1071 isoform switching during cell differentiation Evaluation of statistical methods for normalization 1074 and differential expression in mRNA-Seq experiments Dose-Response Analysis Using R Chemistry-First Approach for Nomination of 1084